EmailStory Stocks®
Archive
Last Update: 20-Dec-12 03:25 ET
Bed Bath & Beyond trades 3% lower after hours post earnings
After Hours Gainers:
Companies trading higher in after hours in reaction to earnings: JBL +5.8%
Companies trading higher in after hours in reaction to news: SD +7.7% (agreed to sell Permian assets for $2.6 bln in cash), WMC +4.1% (declared Q4 dividend of $0.90 per share (prior quarter $0.85 per share) and additional dividend of $0.22 per share), VRSN +0.6% (announced increase in .Net registry fee to $5.62 from $5.11)
After Hours Losers:
Companies trading lower in after hours in reaction to earnings: ACN -4.8%, BBBY -3.8%, PAYX -1.8%, MLHR -1.1%, SCS -0.1%
Companies trading lower in after hours in reaction to news: FOLD -51.5% (announced Phase 3 study of investigational oral migalastat HCl monotherapy in males and females with Fabry disease did not reach its primary endpoint), MDRX -15.2% (announced conclusion of evaluation of strategic alternatives), MITT -2.0% (announced public offering of 3.75 mln shares of common stock), MHLD -1.7% (announces net underwriting impact from Superstorm Sandy; quarterly provision for normalized catastrophe losses $25 -35 mln), ENDP -1.1% (announced that its case against the FDA was dismissed, allowing for a generic non-tamper resistant version of OPANA ER to enter the market on Jan 2, 2013)
Companies trading higher in after hours in reaction to earnings: JBL +5.8%
Companies trading higher in after hours in reaction to news: SD +7.7% (agreed to sell Permian assets for $2.6 bln in cash), WMC +4.1% (declared Q4 dividend of $0.90 per share (prior quarter $0.85 per share) and additional dividend of $0.22 per share), VRSN +0.6% (announced increase in .Net registry fee to $5.62 from $5.11)
After Hours Losers:
Companies trading lower in after hours in reaction to earnings: ACN -4.8%, BBBY -3.8%, PAYX -1.8%, MLHR -1.1%, SCS -0.1%
Companies trading lower in after hours in reaction to news: FOLD -51.5% (announced Phase 3 study of investigational oral migalastat HCl monotherapy in males and females with Fabry disease did not reach its primary endpoint), MDRX -15.2% (announced conclusion of evaluation of strategic alternatives), MITT -2.0% (announced public offering of 3.75 mln shares of common stock), MHLD -1.7% (announces net underwriting impact from Superstorm Sandy; quarterly provision for normalized catastrophe losses $25 -35 mln), ENDP -1.1% (announced that its case against the FDA was dismissed, allowing for a generic non-tamper resistant version of OPANA ER to enter the market on Jan 2, 2013)
